Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01188720
Other study ID # 2010-07-0043
Secondary ID F31MH085416
Status Completed
Phase N/A
First received August 20, 2010
Last updated May 26, 2015
Start date November 2010
Est. completion date August 2013

Study information

Verified date May 2015
Source University of Texas at Austin
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Preliminary findings from a trial in the investigators laboratory suggest that acute exercise may ameliorate deficits in sexual arousal associated with use of antidepressants. The goal of this project is to evaluate the real-world effectiveness of an exercise-based intervention for these side effects in a community-based sample. The investigators hypothesize that general exercise will help improve sexual functioning in women taking antidepressants, and that exercise immediately before sexual activity - that is, acute exercise - will have an additional beneficial effect above and beyond that of general exercise.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date August 2013
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- female

- age 18 or older

- currently receiving a consistent dosage of escitalopram, citalopram, sertraline, desvenlafaxine, venlafaxine, or duloxetine

- currently sexually active

- willing and able to exercise

- experiencing regular menstrual cycles

- not currently pregnant and not intending to become pregnant during trial

Exclusion Criteria:

- currently taking more than one psychoactive medication

- factors indicating risk of cardiovascular activity, including acute or chronic cardiovascular illness, including clinically significant hypertension (defined as self-reported hypertension or "blood pressure greater than 140/90" or receiving medications designed to treat hypertension); recent chest pain; frequent or recurrent faint or dizzy spells; severe or untreated exercise-related asthma; or musculoskeletal illness or injury that would be expected to worsen with physical exercise. Additionally, women will be excluded if they are found to have any of the following as measured during the fitness assessment of the first session: a BMI over 40, waist circumference over 40 inches, waist-to-hip ratio of greater than 0.9, systolic blood pressure greater than 150 or diastolic pressure over 95, or resting heart rate over 90.

- factors associated with significant genital nerve damage, including: previous major pelvic surgery that may have caused nerve damage, including hysterectomy, vulvectomy, circumcision, colostomy, cystostomy, or serious bladder, rectal, or abdominal surgery; or neurological impairment due to diabetes, stroke, pelvic nerve damage secondary to trauma, cancer treatments, myasthenia gravis, multiple sclerosis or spinal cord damage.

- factors associated with non-normative endocrine function, including: perimenopausal or menopausal status, or >1 missed menstrual period in the previous 6 months; or currently pregnant, breastfeeding, or having breastfed within the past 3 months; or reporting clinically significant untreated renal or endocrine disease

- untreated serious mental health conditions

- sexual aversion or distress due to history of unwanted sexual contact

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms

  • Sexual Dysfunction, Physiological
  • Sexual Dysfunctions, Psychological

Intervention

Behavioral:
Physical activity
30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.

Locations

Country Name City State
United States University of Texas at Austin Austin Texas

Sponsors (2)

Lead Sponsor Collaborator
University of Texas at Austin National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sexual Functioning Sexual functioning as measured by the Female Sexual Functioning Index 10 weeks No
Secondary Sexual satisfaction Sexual satisfaction as measured by self-report measure completed weekly throughout the trial Baseline (0 weeks), 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks No
Secondary Sexual Functioning Sexual functioning as measured by the Female Sexual Functioning Index will be measured in between each arm of the trial. 3 weeks, 6 weeks, 9 weeks No
See also
  Status Clinical Trial Phase
Completed NCT00996372 - Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Phase 3
Completed NCT00996164 - Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Phase 3
Recruiting NCT05777031 - Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease Phase 4
Completed NCT00175539 - Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties N/A
Completed NCT04792177 - Internet-based Emotion Regulation Intervention for Sexual Health N/A
Completed NCT02381912 - Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer N/A
Completed NCT03241524 - Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women N/A
Completed NCT00491829 - Flibanserin Versus Placebo in Premenopausal Women With HSDD Phase 3
Completed NCT00034021 - Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction Phase 2
Recruiting NCT05489133 - Early Psychological Intervention After Rape N/A
Completed NCT03775239 - Mindfulness as Treatment of Sexological Problems N/A
Completed NCT01654458 - A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer N/A
Completed NCT01188603 - Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Phase 1
Completed NCT01771237 - HIV Prevention Among Vulnerable Male Youth N/A
Completed NCT00360529 - 24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder Phase 3
Completed NCT00360555 - A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Phase 3
Completed NCT00360243 - 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA Phase 3
Recruiting NCT05456919 - Quality of Sexual Function in BRCA Mutated Women
Terminated NCT01057901 - Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America Phase 3
Terminated NCT01040208 - 12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress Phase 3

External Links